公开(公告)号：EP2983728B1

公开(公告)日：2018-06-06

申请号：EP14783395.8

申请日：2014-04-10

Applicant: Agency for Science, Technology and Research

Inventor： BIRCH, William ,  REUVENY, Shaul ,  OH, Steve ,  LI, Jian

IPC: A61L27/40 ,  C12N5/02 ,  C12N5/074 ,  C12N5/0735 ,  C12N5/0775

CPC classification number: C12N5/0075 ,  A61L27/18 ,  A61L27/34 ,  A61L27/3834 ,  C12N5/0654 ,  C12N2506/1392 ,  C12N2531/00 ,  C12N2533/30 ,  C12N2533/32 ,  C12N2533/40 ,  C12N2533/52 ,  C08L67/04 ,  C08L89/00 ,  C08L5/00

Abstract: A method for manufacturing polycaprolactone microcarriers is disclosed together with uses of the microcarriers.

公开(公告)号：EP3327130A1

公开(公告)日：2018-05-30

申请号：EP16828017.0

申请日：2016-07-18

Applicant: Sungkwang Medical Foundation ,  Cha Biotech Co., Ltd.

Inventor： CHA, Kwang Yul ,  LEE, Dong Ryul ,  CHUNG, Young Gie ,  SONG, Jihwan ,  EUM, Jin Hee

IPC: C12N15/87 ,  C12N5/073

CPC classification number: C12N5/0607 ,  A01N1/0221 ,  C12N5/0018 ,  C12N5/062 ,  C12N5/0665 ,  C12N5/0666 ,  C12N5/0668 ,  C12N5/0696 ,  C12N15/873 ,  C12N2500/46 ,  C12N2506/03 ,  C12N2506/1392 ,  C12N2517/04 ,  C12N2517/10 ,  C12N2760/18821 ,  C12N2760/18822 ,  C12N2760/18831

Abstract: Provided are a storage method and a banking system of cells prepared using somatic cell nuclear transfer (NT) technology with homozygous genotypes of genes of human leukocyte antigen (HLA)-A, HLA-B, HLA-DR, and the like. The banking of NT cell-derived stem cells may be applied to autologous or allogenic patients and can provide transplantable cells and tissue materials for the treatment of various diseases such as diabetes, osteoarthritis, Parkinson's disease, and the like.

公开(公告)号：EP2892997A4

公开(公告)日：2016-04-20

申请号：EP13835201

申请日：2013-09-10

Applicant: UNIV WAKE FOREST HEALTH SCIENCES

Inventor： ZHANG YUANYUAN ,  OPARA EMMANUEL C

IPC: C12N5/00 ,  A61K9/00 ,  A61K9/16 ,  A61K35/22 ,  A61K35/545 ,  A61K38/18 ,  C12N5/071 ,  C12N5/0775

CPC classification number: A61K35/22 ,  A61K9/0019 ,  A61K9/16 ,  A61K35/545 ,  A61K38/18 ,  A61K38/1825 ,  A61K38/1833 ,  A61K38/185 ,  A61K38/1858 ,  A61K38/1866 ,  C12N5/0668 ,  C12N5/0684 ,  C12N5/0685 ,  C12N5/069 ,  C12N2501/165 ,  C12N2506/1392 ,  C12N2506/25

Abstract: Provided herein are methods of treating a subject in need of treatment for a urological condition including administering urine stem cells to said subject in a treatment effective amount; and, in conjunction therewith, administering growth factors to said subject in an amount effective to promote differentiation of said stem cells into skeletal muscle cells. Compositions useful for the same are also provided.

Abstract translation: 本文提供治疗需要治疗泌尿系病症的受试者的方法，包括以治疗有效量向所述受试者施用尿干细胞; 并且与其结合，以有效促进所述干细胞分化成骨骼肌细胞的量向所述受试者施用生长因子。 还提供了对此有用的组合物。

公开(公告)号：EP2573168A1

公开(公告)日：2013-03-27

申请号：EP10849179.6

申请日：2010-07-22

Applicant: Affiliated Hospital Of Ningxia Medical University

Inventor： YANG, Yinxue ,  WEI, Jun ,  LI, Yukui ,  WANG, Libin ,  MA, Lijun ,  LIU, Ting ,  MA, Xiaona ,  FAN, Heng ,  ZHU, Yongzhao ,  YE, Ping ,  JIN, Yiran

IPC: C12N5/0775 ,  C12N5/079 ,  C12N5/02 ,  A61K35/12 ,  A61K35/28 ,  A61K35/50 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  C12R1/91

CPC classification number: C12N5/0619 ,  A61K35/12 ,  A61K35/28 ,  A61K35/30 ,  C12N5/0668 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/13 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2501/91 ,  C12N2502/08 ,  C12N2506/025 ,  C12N2506/1392

Abstract: The present invention belongs to the field of cell transplantation. Particularly, the present invention provides a method of producing neurons for treating injuries with the loss of neuron function from stem cells, wherein the stem cell is a human derived mesenchymal stem cell, preferably human derived placental mesenchymal stem cell, bone marrow mesenchymal stem cell, adipose mesenchymal stem cell and liver mesenchymal stem cell. The present invention also provides the uses of said method and the nerve cells produced by said method in the preparation of medicines for treating injuries with the loss of neuron function and in the treatment of injuries with the loss of neuron function. The present invention further provides a method of treating injuries with the loss of neuron function.

Abstract translation: 本发明属于细胞移植领域。 具体地讲，本发明提供生产用于治疗伤害与神经元功能的自干细胞的损失，worin所述干细胞是来源于人的间充质干细胞的神经元的方法，优选地来自人的胎盘的间充质干细胞，骨髓间充质干细胞， 脂肪间充质干细胞和肝脏间质干细胞。 因此，本发明提供所述方法的用途和通过所述方法中的药物的制备中产生的用于与神经元功能丧失，并与神经元功能丧失损伤的治疗治疗损伤的神经细胞。 本发明进一步提供了与神经元功能丧失治疗损伤的方法。

公开(公告)号：EP2434896A1

公开(公告)日：2012-04-04

申请号：EP10781254.7

申请日：2010-05-28

Applicant: University Of Central Florida Research Foundation, Inc.

Inventor： HICKMAN, James, J. ,  DAVIS, Hedvika

IPC: A01N63/00 ,  C12N5/071

CPC classification number: C12N5/0622 ,  C12N2500/90 ,  C12N2501/01 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/70 ,  C12N2501/81 ,  C12N2501/91 ,  C12N2506/025 ,  C12N2506/1369 ,  C12N2506/1392

Abstract: The invention provides a method of producing oligodendrocytes by in vitro differentiation of human multi-potent progenitor cells (MLPCs). The method comprises culturing isolated MLPCs on a first surface in a serum-free defined culture medium; replacing the culture medium with serum-free culture medium supplemented with bFGF, EGF and PDGF-AA for approximately 24 hours; changing the cultured MLPCs into the supplemented serum-free culture medium further supplemented with differentiation factors norepinephrine, forskolin. and K252a; establishing a 3D environment by covering the culture with a second surface opposite and spaced apart from the first surface, so as to contain the MLPCs therebetween; and continuing to culture until a majority of the MLPCs have differentiated into oligodendrocytes. Additionally included is a method of treatment for a subject afflicted by a disease characterized by central or peripheral nervous system demyelination, the method comprising transplanting into the subject oligodendrocytes produced according to the method disclosed.

公开(公告)号：EP1639096A4

公开(公告)日：2007-09-05

申请号：EP04754973

申请日：2004-06-11

Applicant: ISOLAGEN TECHNOLOGIES INC

Inventor： MARKO OLGA

IPC: C12N5/00 ,  A61K35/12 ,  A61L27/38 ,  C12N5/0793

CPC classification number: A61L27/383 ,  A61K35/12 ,  A61L27/3878 ,  A61L27/3895 ,  C12N5/0619 ,  C12N2500/12 ,  C12N2500/84 ,  C12N2501/113 ,  C12N2506/1384 ,  C12N2506/1392

Abstract: The invention provides a method of producing neurons from undifferentiated mesenchymal cells (UMC). Also featured by the invention is an isolated neuron produced by this method, compositions containing such neurons, and a method of repairing damaged or defective neural tissues using such compositions.

公开(公告)号：EP1659979A1

公开(公告)日：2006-05-31

申请号：EP04707319.2

申请日：2004-02-02

Applicant: Cardio Incorporated

Inventor： MATSUDA, Hikaru ,  SAWA, Yoshiki ,  TAKETANI, Satoshi ,  MIYAGAWA, Shigeru

IPC: A61F2/00 ,  A61L27/38 ,  C12N5/06 ,  A61K31/715

CPC classification number: C12N5/0658 ,  A61K35/12 ,  A61K35/34 ,  A61L27/3804 ,  A61L27/3834 ,  A61L27/3839 ,  A61L27/3895 ,  A61L2430/20 ,  C12N5/0068 ,  C12N5/0657 ,  C12N2506/02 ,  C12N2506/1392 ,  C12N2513/00 ,  C12N2523/00 ,  C12N2533/40 ,  C12N2539/10

Abstract: The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing a prosthetic tissue comprising a cell derived from a part other than myocardium and capable of withstanding implantation operation. The above-described objects of the present invention were partially achieved by finding that by culturing cells under specific culture conditions, the cells are unexpectedly organized into a tissue, and the resultant prosthetic tissue is capable of being detached from culture dishes. The present invention also provides a three-dimensional structure applicable to heart, comprising a cell derived from a part other than the myocardium of an adult.

公开(公告)号：EP1613335A1

公开(公告)日：2006-01-11

申请号：EP04723937.1

申请日：2004-03-29

Applicant: Angioblast Systems Incorporated

Inventor： GRONTHOS, Stan ,  ZANNETTINO, Andrew

IPC: A61K35/12 ,  A61K35/44 ,  A61P9/00 ,  C12N5/06 ,  C12N5/08

CPC classification number: C12N5/0663 ,  A61K9/0014 ,  A61K35/28 ,  A61K35/44 ,  A61K38/00 ,  C12N5/0668 ,  C12N5/0691 ,  C12N2500/42 ,  C12N2501/11 ,  C12N2501/135 ,  C12N2501/165 ,  C12N2501/235 ,  C12N2501/39 ,  C12N2506/1392 ,  A61K2300/00

Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilising a perivascular marker. A new mesenchymal precursor cell phenotype is described characterised by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1 bri . The perivascular mesenchymal precursor cell is multipotential and is shown to form, vascular tissue, as well as bone marrow dentin and pulp. A method of enriching using cell sorting based on these markers is also described.

公开(公告)号：EP2644695B1

公开(公告)日：2018-08-01

申请号：EP13160628.7

申请日：2013-03-22

Applicant: GC Corporation

Inventor： YAMANAKA, Katsuyuki ,  SAKAI, Yuuhiro ,  YAMAMOTO, Katsushi ,  SHIGEMITSU, Yusuke

IPC: C12N5/077 ,  C12N5/074 ,  C12N5/0775 ,  A61F2/30 ,  A61L27/38

CPC classification number: A61K35/32 ,  A61L27/18 ,  A61L27/3817 ,  A61L27/58 ,  A61L2430/06 ,  C12N5/0655 ,  C12N5/0663 ,  C12N5/0668 ,  C12N2506/1353 ,  C12N2506/1392 ,  C12N2533/40 ,  C08L67/04

Abstract: Provided is a cultured cartilage tissue material which enables formation of cartilage tissue being substantially the same as the cartilage tissue actually in the living body, and which is large in volume. The cultured cartilage tissue material is to be used for cartilage regeneration and comprises chondrocytes, and is a mixed body of chondrocytes in a concentration of 1 x 10 7 to 1 × 10 9 cells/cm 3 , and a bioabsorbable polymer. A thickness of the thinnest part of the cultured cartilage tissue material is 2.2 to 100 mm. A volume ratio between the chondrocytes and the bioabsorbable polymer is 7:3 to 9.5:0.5. A production amount of glycosaminoglycan is 0.001 to 0.2 ng per unit cell. A content ratio between type I collagen and type II collagen is 10:90 to 1: 99. A content of type II collagen is 0.01 to 0.65 mg per 1 mg of dry weight of tissue.

公开(公告)号：EP2380969B1

公开(公告)日：2018-07-04

申请号：EP11155631.2

申请日：2004-03-29

Applicant: Mesoblast, Inc.

Inventor： Gronthos, Stan ,  Zannettino, Andrew

IPC: C12N5/00 ,  C12N5/0775 ,  A61K35/28

CPC classification number: C12N5/0663 ,  A61K9/0014 ,  A61K35/28 ,  A61K35/44 ,  A61K38/00 ,  C12N5/0668 ,  C12N5/0691 ,  C12N2500/42 ,  C12N2501/11 ,  C12N2501/135 ,  C12N2501/165 ,  C12N2501/235 ,  C12N2501/39 ,  C12N2506/1392 ,  A61K2300/00

Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilising a perivascular marker. A new mesenchymal precursor cell phenotype is described characterised by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1 bri . The perivascular mesenchymal precursor cell is multipotential and is shown to form, vascular tissue, as well as bone marrow dentin and pulp. A method of enriching using cell sorting based on these markers is also described.